Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensification Regimen for Resectable Advanced Head and Neck Cancer
NCT00566540Phase 2Terminated
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Dec 2007
- Primary completion
- Feb 2010
- Modality
- Nanoparticles, Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Cisplatin micelle injection (HA132) and Paclitaxel Micelles for Injection in head and neck squamous cell carcinoma (HNSCC), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoint: Feasibility of Treatment at 1 year. Started Dec 2007; status: terminated.
02
Drugs
Cisplatin micelle injection (HA132)Paclitaxel Micelles for Injection
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00566540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00566540.